New Approaches to Cocaine Abuse Medications (B) - 7

This study has been completed.

First Received: September 20, 1999 Last Updated: June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	New York State Psychiatric Institute
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000272

Purpose

The purpose of this study is to measure the effect of risperidone in cocaine abusers.

Condition	Intervention	Phase
Cocaine-Related Disorders Substance-Related Disorders	Drug: Risperidone	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	New Approaches to Cocaine Abuse Medications (B)

Resource links provided by NLM:

Drug Information available for: Risperidone

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Side effects
Craving
Drug use
Retention
Depression

Estimated Enrollment:	0
Study Start Date:	March 1995

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000272

Locations

United States, New York
Research Foundation for Mental Hygiene
New York, New York, United States, 10032

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

New York State Psychiatric Institute

Investigators

Principal Investigator:

Herbert Kleber, M.D.

New York State Psychiatric Institute

More Information

No publications provided

Study ID Numbers:	NIDA-09236-7, P50-09236-7
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000272 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Neurotransmitter Agents
Tranquilizing Agents
Disease
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Risperidone
Central Nervous System Depressants
Disorders of Environmental Origin
Dopamine Antagonists

Antipsychotic Agents
Pharmacologic Actions
Serotonin Antagonists
Pathologic Processes
Serotonin Agents
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Dopamine Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 09, 2009